Skip to main content
Top
Published in: Gastric Cancer 6/2022

Open Access 07-08-2022 | Gastric Cancer | Original Article

Survival trends in gastric cancer patients between 1987 and 2016: a population-based cohort study in Finland

Authors: Urgena Maharjan, Joonas H. Kauppila

Published in: Gastric Cancer | Issue 6/2022

Login to get access

Abstract

Background

Gastric cancer is the fourth leading cause of cancer-related deaths globally. There is a paucity of national studies examining gastric cancer mortality in relation to treatment status. This study evaluated the survival trends in gastric adenocarcinoma and all gastric cancers stratified by treatment in Finland during 1987–2016.

Methods

This population-based, nationwide, retrospective cohort study included all gastric cancer patients registered in the Finnish Cancer Registry and Patient Registry. The survival rates were calculated for 1, 3, and 5 years, stratified by treatment. Prognostic factors were determined using Cox regression.

Results

A total of 18,713 non-cardia gastric adenocarcinoma, and 3617 cardia adenocarcinoma patients were included. Surgical treatment decreased for non-cardia adenocarcinoma and remained constant for cardia adenocarcinoma. In non-cardia adenocarcinoma, the 5-year survival declined from 17% to 16% from 1987–1991 to 2012–2016. In surgically treated patients, survival increased from 29% to 38%, while an increase from 4% to 7% in those undergoing chemotherapy and decrease from 6% to 3% in those not receiving any treatment were observed. In cardia adenocarcinoma, the 5-year survival increased from 10% to 18% in all patients, 16% to 40% in surgical patients, 0% to 5% in patients receiving chemotherapy, and from 5% to 9% in patients receiving no treatment. Earlier calendar periods, older age, male sex, and higher comorbidity were risk factors for poor prognosis.

Conclusions

Gastric non-cardia adenocarcinoma survival declined, limited to advanced stage patients not receiving any treatment. Gastric cardia cancer survival seems to have improved over time in Finland.

Mini abstract

This study evaluated survival trends of gastric cancer in Finland during 1987–2016 and established that the 5-year survival is declining in non-cardia adenocarcinoma but improving in all gastric cancers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin. 2021;71(3):209–49.CrossRef Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin. 2021;71(3):209–49.CrossRef
2.
go back to reference Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3(3):251–61.PubMedPubMedCentral Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3(3):251–61.PubMedPubMedCentral
3.
go back to reference Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015;64(12):1881.CrossRef Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut. 2015;64(12):1881.CrossRef
4.
go back to reference Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–49.CrossRef Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–49.CrossRef
5.
go back to reference den Hoed CM, Kuipers EJ. Gastric cancer: how can we reduce the incidence of this disease? Curr Gastroenterol Rep. 2016;18(7):34.CrossRef den Hoed CM, Kuipers EJ. Gastric cancer: how can we reduce the incidence of this disease? Curr Gastroenterol Rep. 2016;18(7):34.CrossRef
6.
go back to reference Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–62.CrossRef Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–62.CrossRef
7.
go back to reference Lv L, Liang X, Wu D, Wang F, Zhang Y, Cang H, et al. Is cardia cancer a special type of gastric cancer? A differential analysis of early cardia cancer and non-cardia cancer. J Cancer. 2021;12(8):2385–94.CrossRef Lv L, Liang X, Wu D, Wang F, Zhang Y, Cang H, et al. Is cardia cancer a special type of gastric cancer? A differential analysis of early cardia cancer and non-cardia cancer. J Cancer. 2021;12(8):2385–94.CrossRef
8.
go back to reference Bornschein J, Selgrad M, Warnecke M, Kuester D, Wex T, Malfertheiner PH. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci. 2010;55(11):3124–31.CrossRef Bornschein J, Selgrad M, Warnecke M, Kuester D, Wex T, Malfertheiner PH. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci. 2010;55(11):3124–31.CrossRef
9.
go back to reference Maeda H, Okabayashi T, Nishimori I, Sugimoto T, Namikawa T, Dabanaka K, et al. Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach? J Am Coll Surg. 2008;206(2):306–10.CrossRef Maeda H, Okabayashi T, Nishimori I, Sugimoto T, Namikawa T, Dabanaka K, et al. Clinicopathologic features of adenocarcinoma at the gastric cardia: is it different from distal cancer of the stomach? J Am Coll Surg. 2008;206(2):306–10.CrossRef
10.
go back to reference Anderson LA, Tavilla A, Brenner H, Luttmann S, Navarro C, Gavin AT, et al. Survival for oesophageal, stomach and small intestine cancers in Europe 1999–2007: results from EUROCARE-5. Eur J Cancer. 2015;51(15):2144–57.CrossRef Anderson LA, Tavilla A, Brenner H, Luttmann S, Navarro C, Gavin AT, et al. Survival for oesophageal, stomach and small intestine cancers in Europe 1999–2007: results from EUROCARE-5. Eur J Cancer. 2015;51(15):2144–57.CrossRef
11.
go back to reference Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Allemani C, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer. 2009;45(6):1042–66.CrossRef Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Allemani C, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer. 2009;45(6):1042–66.CrossRef
12.
go back to reference Matsuda T, Saika K. The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan. Jpn J Clin Oncol. 2013;43(11):1157–8.CrossRef Matsuda T, Saika K. The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan. Jpn J Clin Oncol. 2013;43(11):1157–8.CrossRef
13.
go back to reference Asplund J, Kauppila JH, Mattsson F, Lagergren J. Survival trends in gastric adenocarcinoma: a population-based study in Sweden. Ann Surg Oncol. 2018;25(9):2693–702.CrossRef Asplund J, Kauppila JH, Mattsson F, Lagergren J. Survival trends in gastric adenocarcinoma: a population-based study in Sweden. Ann Surg Oncol. 2018;25(9):2693–702.CrossRef
14.
go back to reference Kauppila JH, Ohtonen P, Rantanen T, Tyrväinen T, Toikkanen V, Pääaho M, et al. Cohort profile: gastric cancer in the population-based, Finnish National Esophago-Gastric Cancer Cohort (FINEGO) Study. BMJ Open. 2020;10(10): e039574.CrossRef Kauppila JH, Ohtonen P, Rantanen T, Tyrväinen T, Toikkanen V, Pääaho M, et al. Cohort profile: gastric cancer in the population-based, Finnish National Esophago-Gastric Cancer Cohort (FINEGO) Study. BMJ Open. 2020;10(10): e039574.CrossRef
15.
go back to reference Kauppila JH, Ohtonen P, Karttunen TJ, Kokkola A, Laine S, Rantanen T, et al. Finnish National Esophago-Gastric Cancer Cohort (FINEGO) for studying outcomes after oesophageal and gastric cancer surgery: a protocol for a retrospective, population-based, nationwide cohort study in Finland. BMJ Open. 2019;9(1): e024094.CrossRef Kauppila JH, Ohtonen P, Karttunen TJ, Kokkola A, Laine S, Rantanen T, et al. Finnish National Esophago-Gastric Cancer Cohort (FINEGO) for studying outcomes after oesophageal and gastric cancer surgery: a protocol for a retrospective, population-based, nationwide cohort study in Finland. BMJ Open. 2019;9(1): e024094.CrossRef
16.
go back to reference Leinonen MK, Miettinen J, Heikkinen S, Pitkäniemi J, Malila N. Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours. Eur J Cancer. 2017;77:31–9.CrossRef Leinonen MK, Miettinen J, Heikkinen S, Pitkäniemi J, Malila N. Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours. Eur J Cancer. 2017;77:31–9.CrossRef
17.
go back to reference Sund R. Quality of the Finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40(6):505–15.CrossRef Sund R. Quality of the Finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40(6):505–15.CrossRef
19.
go back to reference Maharjan U, Kauppila JH. Gastric cancer completeness in Finnish Cancer Registry and Finnish Patient Registry: a population-based nationwide retrospective cohort study. BMJ Open. 2022;12(4):e056320 (Published 2022 Apr 19).CrossRef Maharjan U, Kauppila JH. Gastric cancer completeness in Finnish Cancer Registry and Finnish Patient Registry: a population-based nationwide retrospective cohort study. BMJ Open. 2022;12(4):e056320 (Published 2022 Apr 19).CrossRef
20.
go back to reference Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, et al. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in The Netherlands. Eur J Cancer. 2010;46(6):1101–10.CrossRef Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, et al. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in The Netherlands. Eur J Cancer. 2010;46(6):1101–10.CrossRef
21.
go back to reference Young JA, Shimi SM, Kerr L, McPhillips G, Thompson AM. Reduction in gastric cancer surgical mortality over 10 years: an adverse events analysis. Ann Med Surg (Lond). 2014;3(2):26–30.CrossRef Young JA, Shimi SM, Kerr L, McPhillips G, Thompson AM. Reduction in gastric cancer surgical mortality over 10 years: an adverse events analysis. Ann Med Surg (Lond). 2014;3(2):26–30.CrossRef
22.
go back to reference Nelen SD, Heuthorst L, Verhoeven RHA, Polat F, Kruyt PM, Reijnders K, et al. Impact of centralizing gastric cancer surgery on treatment, morbidity, and mortality. J Gastrointest Surg. 2017;21(12):2000–8.CrossRef Nelen SD, Heuthorst L, Verhoeven RHA, Polat F, Kruyt PM, Reijnders K, et al. Impact of centralizing gastric cancer surgery on treatment, morbidity, and mortality. J Gastrointest Surg. 2017;21(12):2000–8.CrossRef
23.
go back to reference Jim MA, Pinheiro PS, Carreira H, Espey DK, Wiggins CL, Weir HK. Stomach cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer. 2017;123(Suppl 24):4994–5013.CrossRef Jim MA, Pinheiro PS, Carreira H, Espey DK, Wiggins CL, Weir HK. Stomach cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer. 2017;123(Suppl 24):4994–5013.CrossRef
24.
go back to reference Hong S, Won Y, Park YR, Jung K, Kong H, Lee ES, et al. Cancer Statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat. 2020;52(2):335–50.CrossRef Hong S, Won Y, Park YR, Jung K, Kong H, Lee ES, et al. Cancer Statistics in Korea: incidence, mortality, survival, and prevalence in 2017. Cancer Res Treat. 2020;52(2):335–50.CrossRef
25.
go back to reference Zhang H, Liu Q. Prognostic indicators for gastrointestinal stromal tumors: a review. Transl Oncol. 2020;13(10): 100812.CrossRef Zhang H, Liu Q. Prognostic indicators for gastrointestinal stromal tumors: a review. Transl Oncol. 2020;13(10): 100812.CrossRef
26.
go back to reference Kargwal N, Panda V, Jha A, Singh CB. Gastric neuroendocrine tumor. Surg J (N Y). 2021;7(3):e142–6.CrossRef Kargwal N, Panda V, Jha A, Singh CB. Gastric neuroendocrine tumor. Surg J (N Y). 2021;7(3):e142–6.CrossRef
27.
go back to reference Lumbreras B, Donat L, Hernández-Aguado I. Incidental findings in imaging diagnostic tests: a systematic review. Br J Radiol. 2010;83(988):276–89.CrossRef Lumbreras B, Donat L, Hernández-Aguado I. Incidental findings in imaging diagnostic tests: a systematic review. Br J Radiol. 2010;83(988):276–89.CrossRef
28.
go back to reference Lou L, Wang L, Zhang Y, Chen G, Lin L, Jin X, et al. Sex difference in incidence of gastric cancer: an international comparative study based on the Global Burden of Disease Study 2017. BMJ Open. 2020;10(1): e033323.CrossRef Lou L, Wang L, Zhang Y, Chen G, Lin L, Jin X, et al. Sex difference in incidence of gastric cancer: an international comparative study based on the Global Burden of Disease Study 2017. BMJ Open. 2020;10(1): e033323.CrossRef
29.
go back to reference Blanc-Lapierre A, Rousseau M, Weiss D, El-Zein M, Siemiatycki J, Parent M. Lifetime report of perceived stress at work and cancer among men: a case–control study in Montreal, Canada. Prev Med. 2017;96:28–35.CrossRef Blanc-Lapierre A, Rousseau M, Weiss D, El-Zein M, Siemiatycki J, Parent M. Lifetime report of perceived stress at work and cancer among men: a case–control study in Montreal, Canada. Prev Med. 2017;96:28–35.CrossRef
30.
go back to reference Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187–96.CrossRef Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187–96.CrossRef
31.
go back to reference McQueen A, Vernon SW, Meissner HI, Rakowski W. Risk perceptions and worry about cancer: does gender make a difference? J Health Commun. 2008;13(1):56–79.CrossRef McQueen A, Vernon SW, Meissner HI, Rakowski W. Risk perceptions and worry about cancer: does gender make a difference? J Health Commun. 2008;13(1):56–79.CrossRef
32.
go back to reference Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(1):20.CrossRef Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(1):20.CrossRef
33.
go back to reference Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer. 2008;44(16):2397–403.CrossRef Chandanos E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer. 2008;44(16):2397–403.CrossRef
34.
go back to reference Sheh A, Ge Z, Parry NMA, Muthupalani S, Rager JE, Raczynski AR, et al. 17β-Estradiol and tamoxifen prevent gastric cancer by modulating leukocyte recruitment and oncogenic pathways in Helicobacter pylori-infected INS-GAS male mice. Cancer Prev Res (Phila). 2011;4(9):1426.CrossRef Sheh A, Ge Z, Parry NMA, Muthupalani S, Rager JE, Raczynski AR, et al. 17β-Estradiol and tamoxifen prevent gastric cancer by modulating leukocyte recruitment and oncogenic pathways in Helicobacter pylori-infected INS-GAS male mice. Cancer Prev Res (Phila). 2011;4(9):1426.CrossRef
Metadata
Title
Survival trends in gastric cancer patients between 1987 and 2016: a population-based cohort study in Finland
Authors
Urgena Maharjan
Joonas H. Kauppila
Publication date
07-08-2022
Publisher
Springer Nature Singapore
Published in
Gastric Cancer / Issue 6/2022
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-022-01326-5

Other articles of this Issue 6/2022

Gastric Cancer 6/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.